MCID: ACN003
MIFTS: 37

Acneiform Dermatitis

Categories: Skin diseases

Aliases & Classifications for Acneiform Dermatitis

MalaCards integrated aliases for Acneiform Dermatitis:

Name: Acneiform Dermatitis 12 15 17
Dermatitis Acneiform 70

Classifications:



External Ids:

Disease Ontology 12 DOID:4399
NCIt 50 C35277
UMLS 70 C0234894

Summaries for Acneiform Dermatitis

MalaCards based summary : Acneiform Dermatitis, also known as dermatitis acneiform, is related to exanthem and lung cancer. An important gene associated with Acneiform Dermatitis is HRAS (HRas Proto-Oncogene, GTPase), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. Affiliated tissues include lung, thyroid and colon, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Acneiform Dermatitis

Diseases related to Acneiform Dermatitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 202)
# Related Disease Score Top Affiliating Genes
1 exanthem 29.6 KRAS HRAS EGFR CYP3A4
2 lung cancer 28.1 NRAS MAP2K1 KRAS HRAS ERBB4 EGFR
3 hepatic flexure cancer 10.3 KRAS HRAS
4 trachea carcinoma in situ 10.3 KRAS HRAS
5 signet ring basal cell carcinoma 10.3 KRAS HRAS
6 cobblestone retinal degeneration 10.3 KRAS HRAS
7 immature teratoma of ovary 10.3 KRAS HRAS
8 pancreatic signet ring cell adenocarcinoma 10.2 KRAS HRAS
9 signet ring cell adenocarcinoma 10.2 KRAS HRAS
10 keratosis pilaris atrophicans faciei 10.2 MAP2K1 EGFR
11 adenocarcinoma in situ 10.2 KRAS EGFR
12 descending colon cancer 10.2 KRAS HRAS
13 ampulla of vater benign neoplasm 10.2 KRAS HRAS
14 transverse colon cancer 10.2 KRAS HRAS
15 periampullary adenoma 10.2 KRAS HRAS
16 bone giant cell sarcoma 10.2 KRAS HRAS
17 appendiceal neoplasm 10.2 KRAS HRAS
18 gallbladder benign neoplasm 10.2 KRAS HRAS
19 appendix adenocarcinoma 10.2 KRAS HRAS
20 mucinous lung adenocarcinoma 10.2 KRAS HRAS
21 wolffian duct adenocarcinoma 10.2 KRAS HRAS
22 noonan syndrome-like disorder with loose anagen hair 1 10.2 KRAS HRAS
23 meningeal melanomatosis 10.2 NRAS HRAS
24 myh-associated polyposis 10.2 KRAS HRAS
25 ascending colon cancer 10.2 KRAS HRAS
26 biliary tract benign neoplasm 10.2 KRAS HRAS
27 malignant anus melanoma 10.2 NRAS HRAS
28 conjunctival nevus 10.2 NRAS HRAS
29 malignant dermis tumor 10.2 NRAS HRAS
30 ovarian mucinous neoplasm 10.2 KRAS HRAS
31 central nervous system melanocytic neoplasm 10.2 NRAS HRAS
32 malignant exocrine pancreas neoplasm 10.2 KRAS HRAS
33 malignant skin fibrous histiocytoma 10.2 NRAS HRAS
34 pancreatic acinar cell adenocarcinoma 10.2 KRAS HRAS
35 prostate squamous cell carcinoma 10.2 MAP2K1 HRAS
36 vulvar melanoma 10.2 NRAS HRAS
37 appendix disease 10.2 KRAS HRAS
38 bile duct cysts 10.2 KRAS HRAS
39 pulmonary valve disease 10.2 MAP2K1 HRAS
40 small intestine adenocarcinoma 10.2 KRAS HRAS
41 papillary adenoma 10.2 KRAS HRAS
42 appendix cancer 10.2 KRAS HRAS
43 duodenum adenocarcinoma 10.2 KRAS HRAS
44 nasal cavity adenocarcinoma 10.2 KRAS HRAS
45 spitz nevus 10.2 HRAS BRAF
46 eccrine papillary adenoma 10.2 KRAS HRAS
47 myasthenic syndrome, congenital, 14 10.2 KRAS HRAS
48 struma ovarii 10.2 KRAS BRAF
49 malignant conjunctival melanoma 10.2 NRAS HRAS
50 rectosigmoid cancer 10.2 KRAS HRAS

Graphical network of the top 20 diseases related to Acneiform Dermatitis:



Diseases related to Acneiform Dermatitis

Symptoms & Phenotypes for Acneiform Dermatitis

GenomeRNAi Phenotypes related to Acneiform Dermatitis according to GeneCards Suite gene sharing:

26 (show all 16)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.65 BRAF KRAS EGFR HRAS
2 Decreased viability GR00055-A-2 10.65 BRAF KRAS EGFR HRAS
3 Decreased viability GR00055-A-3 10.65 KRAS
4 Decreased viability GR00106-A-0 10.65 KRAS
5 Decreased viability GR00221-A-1 10.65 KRAS CRKL EGFR HRAS NRAS
6 Decreased viability GR00221-A-2 10.65 KRAS CRKL HRAS
7 Decreased viability GR00221-A-3 10.65 HRAS NRAS
8 Decreased viability GR00221-A-4 10.65 BRAF CRKL EGFR
9 Decreased viability GR00249-S 10.65 BRAF CRKL
10 Decreased viability GR00301-A 10.65 BRAF ERBB4 KRAS
11 Decreased viability GR00342-S-1 10.65 ERBB4
12 Decreased viability GR00381-A-1 10.65 BRAF KRAS
13 Decreased cell migration GR00055-A-3 9.8 BRAF EGFR HRAS
14 Decreased Hepatitis C Virus pseudoparticles (HCVpp; H77; genotype 1a) infection GR00234-A-1 9.43 BRAF EGFR ERBB4
15 Reduced mammosphere formation GR00396-S 9.1 BRAF CRKL EGFR HRAS KRAS NRAS
16 Decreased viability in Von Hippel-Lindau (VHL) (-/-) cell line GR00121-A 8.96 ERBB4 MAP2K1

MGI Mouse Phenotypes related to Acneiform Dermatitis:

46 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.14 BRAF CRKL EGFR ERBB4 HRAS KRAS
2 craniofacial MP:0005382 10.13 BRAF CRKL EGFR ERBB4 HRAS KRAS
3 endocrine/exocrine gland MP:0005379 10.08 BRAF CRKL EGFR ERBB4 HRAS KRAS
4 embryo MP:0005380 10.04 BRAF CRKL EGFR ERBB4 KRAS MAP2K1
5 integument MP:0010771 10.03 BRAF CRKL EGFR ERBB4 HRAS KRAS
6 digestive/alimentary MP:0005381 9.99 BRAF EGFR HRAS KRAS MAP2K1 NRAS
7 mortality/aging MP:0010768 9.97 BRAF CRKL EGFR ERBB4 HRAS KRAS
8 neoplasm MP:0002006 9.87 BRAF CRKL EGFR HRAS KRAS MAP2K1
9 hearing/vestibular/ear MP:0005377 9.85 BRAF CRKL EGFR KRAS MAP2K1
10 limbs/digits/tail MP:0005371 9.8 BRAF CRKL EGFR KRAS NRAS
11 normal MP:0002873 9.8 BRAF EGFR ERBB4 HRAS KRAS MAP2K1
12 skeleton MP:0005390 9.5 BRAF CRKL EGFR HRAS KRAS MAP2K1
13 pigmentation MP:0001186 9.46 BRAF EGFR KRAS NRAS
14 vision/eye MP:0005391 9.1 BRAF CRKL EGFR KRAS MAP2K1 NRAS

Drugs & Therapeutics for Acneiform Dermatitis

Search Clinical Trials , NIH Clinical Center for Acneiform Dermatitis

Genetic Tests for Acneiform Dermatitis

Anatomical Context for Acneiform Dermatitis

MalaCards organs/tissues related to Acneiform Dermatitis:

40
Lung, Thyroid, Colon, Skin, Myeloid, Brain, Ovary

Publications for Acneiform Dermatitis

Articles related to Acneiform Dermatitis:

(show top 50) (show all 88)
# Title Authors PMID Year
1
Results of the non-small cell lung cancer part of a phase III, open-label, randomized trial evaluating topical corticosteroid therapy for facial acneiform dermatitis induced by EGFR inhibitors: stepwise rank down from potent corticosteroid (FAEISS study, NCCH-1512). 61
32918131 2021
2
Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase III IMspire170 study. 61
33309774 2021
3
The EMA assessment of encorafenib in combination with cetuximab for the treatment of adult patients with metastatic colorectal carcinoma harbouring the BRAFV600E mutation who have received prior therapy. 61
33422765 2021
4
A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors. 61
32737717 2021
5
Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. 61
33331989 2021
6
Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050). 61
33721611 2021
7
Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors. 61
33170484 2021
8
Safety and Efficacy of the Sirolimus Gel for TSC Patients With Facial Skin Lesions in a Long-Term, Open-Label, Extension, Uncontrolled Clinical Trial. 61
32385845 2020
9
Cutaneous Reactions in Children Treated with MEK Inhibitors, BRAF Inhibitors, or Combination Therapy: A Multi-Center Study. 61
32682884 2020
10
Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. 61
32615108 2020
11
Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study. 61
31954624 2020
12
Safety and efficacy of first-line dacomitinib in Japanese patients with advanced non-small cell lung cancer. 61
32159882 2020
13
A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer. 61
31645440 2020
14
Efficacy of EGFR-TKIs with or without angiogenesis inhibitors in advanced non-small-cell lung cancer: A systematic review and meta-analysis. 61
31942192 2020
15
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. 61
31591063 2019
16
A phase 1b study evaluating the safety and pharmacokinetics of regorafenib in combination with cetuximab in patients with advanced solid tumors. 61
30958892 2019
17
Molecular and Clinical Activity of CDX-3379, an Anti-ErbB3 Monoclonal Antibody, in Head and Neck Squamous Cell Carcinoma Patients. 61
31308059 2019
18
Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation. 61
30529597 2019
19
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan. 61
30797492 2019
20
A phase 1b study of afatinib in combination with standard-dose cetuximab in patients with advanced solid tumours. 61
30278378 2018
21
Phase I dose-escalation trial of Sym004, an anti-EGFR antibody mixture, in Japanese patients with advanced solid tumors. 61
30099818 2018
22
A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer. 61
29926131 2018
23
Vemurafenib in Chinese patients with BRAFV600 mutation-positive unresectable or metastatic melanoma: an open-label, multicenter phase I study. 61
29724167 2018
24
First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study. 61
29247021 2018
25
Molecular Docking for Prediction and Interpretation of Adverse Drug Reactions. 61
29792141 2018
26
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. 61
28958502 2017
27
A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS. 61
28592615 2017
28
A Phase I Clinical Trial and Independent Patient-Derived Xenograft Study of Combined Targeted Treatment with Dacomitinib and Figitumumab in Advanced Solid Tumors. 61
27733479 2017
29
A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors. 61
27650277 2017
30
A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor. 61
28152546 2017
31
Dalotuzumab in chemorefractory KRAS exon 2 mutant colorectal cancer: Results from a randomised phase II/III trial. 61
27681944 2017
32
Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: Phase II randomized study in women with endocrine-therapy-naïve advanced breast cancer. 61
27654971 2016
33
A Randomized Phase 2 Study Comparing the Combination of Ficlatuzumab and Gefitinib with Gefitinib Alone in Asian Patients with Advanced Stage Pulmonary Adenocarcinoma. 61
27448761 2016
34
A phase I dose-escalation study of LY2875358, a bivalent MET antibody, given as monotherapy or in combination with erlotinib or gefitinib in Japanese patients with advanced malignancies. 61
27422720 2016
35
Effect of an Outreach Programme on Vandetanib Safety in Medullary Thyroid Cancer. 61
27843809 2016
36
Everolimus safety and efficacy for renal angiomyolipomas associated with tuberous sclerosis complex: a Spanish expanded access trial. 61
27669821 2016
37
Doublet BRAF/MEK inhibition versus single-agent BRAF inhibition in the management of BRAF-mutant advanced melanoma, biological rationale and meta-analysis of published data. 61
26519363 2016
38
PRISM: Phase 2 trial with panitumumab monotherapy as second-line treatment in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. 61
26681429 2016
39
Gefitinib as first line therapy in Malaysian patients with EGFR mutation-positive non-small-cell lung cancer: A single-center retrospective study. 61
27073548 2016
40
Phase I and pharmacokinetics/pharmacodynamics study of the MEK inhibitor RO4987655 in Japanese patients with advanced solid tumors. 61
25809858 2015
41
A phase 1 study of ABT-806 in subjects with advanced solid tumors. 61
25895099 2015
42
A neoadjuvant, randomized, open-label phase II trial of afatinib versus trastuzumab versus lapatinib in patients with locally advanced HER2-positive breast cancer. 61
25537159 2015
43
Risk of selected dermatological toxicities in cancer patients treated with MEK inhibitors: a comparative systematic review and meta-analysis. 61
26561878 2015
44
Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma. 61
25417902 2015
45
Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial. 61
25456362 2014
46
Phase 2, open-label, 1:1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-naïve patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). 61
24894651 2014
47
Safety and efficacy of dacomitinib in korean patients with KRAS wild-type advanced non-small-cell lung cancer refractory to chemotherapy and erlotinib or gefitinib: a phase I/II trial. 61
25521398 2014
48
Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations. 61
24947927 2014
49
A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib. 61
24501009 2014
50
Phase I dose-escalation study of oral vinflunine in combination with erlotinib in pre-treated and unselected EGFR patients with locally advanced or metastatic non-small-cell lung cancer. 61
24220936 2014

Variations for Acneiform Dermatitis

Expression for Acneiform Dermatitis

Search GEO for disease gene expression data for Acneiform Dermatitis.

Pathways for Acneiform Dermatitis

Pathways related to Acneiform Dermatitis according to GeneCards Suite gene sharing:

(show top 50) (show all 183)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.12 NRAS MAP2K1 KRAS HRAS ERBB4 EGFR
2
Show member pathways
14 NRAS MAP2K1 KRAS HRAS ERBB4 EGFR
3
Show member pathways
13.81 NRAS MAP2K1 KRAS HRAS ERBB4 EGFR
4
Show member pathways
13.78 NRAS MAP2K1 KRAS HRAS EGFR BRAF
5
Show member pathways
13.71 NRAS MAP2K1 KRAS HRAS ERBB4 EGFR
6
Show member pathways
13.71 NRAS MAP2K1 KRAS HRAS ERBB4 EGFR
7
Show member pathways
13.68 NRAS MAP2K1 KRAS HRAS ERBB4 EGFR
8
Show member pathways
13.58 NRAS MAP2K1 KRAS HRAS ERBB4 EGFR
9
Show member pathways
13.58 NRAS MAP2K1 KRAS HRAS ERBB4 EGFR
10
Show member pathways
13.53 NRAS MAP2K1 KRAS HRAS ERBB4 EGFR
11
Show member pathways
13.46 NRAS MAP2K1 KRAS HRAS ERBB4 BRAF
12
Show member pathways
13.42 NRAS MAP2K1 KRAS HRAS EGFR BRAF
13
Show member pathways
13.42 NRAS MAP2K1 KRAS HRAS ERBB4 EGFR
14
Show member pathways
13.41 NRAS KRAS HRAS ERBB4 EGFR
15
Show member pathways
13.37 NRAS KRAS HRAS ERBB4 EGFR
16
Show member pathways
13.35 NRAS MAP2K1 KRAS HRAS ERBB4 EGFR
17
Show member pathways
13.34 NRAS MAP2K1 KRAS HRAS ERBB4 EGFR
18
Show member pathways
13.26 NRAS MAP2K1 KRAS HRAS EGFR BRAF
19
Show member pathways
13.14 NRAS MAP2K1 KRAS HRAS EGFR BRAF
20
Show member pathways
13.1 NRAS MAP2K1 KRAS HRAS EGFR CRKL
21
Show member pathways
13.09 NRAS MAP2K1 KRAS HRAS EGFR
22
Show member pathways
13.08 NRAS MAP2K1 KRAS HRAS EGFR
23
Show member pathways
13.08 NRAS MAP2K1 KRAS HRAS CRKL BRAF
24
Show member pathways
13.07 NRAS MAP2K1 KRAS HRAS ERBB4 EGFR
25
Show member pathways
13.03 NRAS MAP2K1 KRAS HRAS EGFR CRKL
26
Show member pathways
13 NRAS MAP2K1 KRAS HRAS EGFR BRAF
27
Show member pathways
13 NRAS MAP2K1 KRAS HRAS EGFR CRKL
28
Show member pathways
12.99 NRAS MAP2K1 KRAS HRAS CRKL BRAF
29
Show member pathways
12.98 NRAS MAP2K1 KRAS HRAS BRAF
30
Show member pathways
12.96 NRAS MAP2K1 KRAS HRAS ERBB4 EGFR
31
Show member pathways
12.95 NRAS MAP2K1 KRAS HRAS EGFR CRKL
32 12.93 NRAS MAP2K1 KRAS HRAS EGFR CRKL
33
Show member pathways
12.92 NRAS MAP2K1 KRAS HRAS ERBB4 EGFR
34
Show member pathways
12.88 NRAS MAP2K1 KRAS HRAS BRAF
35
Show member pathways
12.88 NRAS MAP2K1 KRAS HRAS EGFR BRAF
36
Show member pathways
12.88 NRAS MAP2K1 KRAS HRAS EGFR CRKL
37
Show member pathways
12.87 NRAS MAP2K1 KRAS HRAS BRAF
38
Show member pathways
12.87 NRAS MAP2K1 KRAS HRAS EGFR CRKL
39
Show member pathways
12.86 MAP2K1 KRAS HRAS CRKL BRAF
40
Show member pathways
12.84 NRAS MAP2K1 KRAS HRAS CRKL BRAF
41
Show member pathways
12.82 NRAS KRAS HRAS ERBB4 EGFR
42
Show member pathways
12.81 NRAS MAP2K1 KRAS HRAS EGFR BRAF
43
Show member pathways
12.81 NRAS MAP2K1 KRAS HRAS EGFR CRKL
44
Show member pathways
12.8 NRAS MAP2K1 KRAS HRAS EGFR BRAF
45
Show member pathways
12.79 NRAS MAP2K1 KRAS HRAS EGFR BRAF
46
Show member pathways
12.78 NRAS MAP2K1 KRAS HRAS EGFR BRAF
47
Show member pathways
12.75 NRAS MAP2K1 KRAS HRAS BRAF
48
Show member pathways
12.74 NRAS MAP2K1 KRAS HRAS
49
Show member pathways
12.73 NRAS MAP2K1 KRAS HRAS EGFR CRKL
50 12.73 NRAS MAP2K1 KRAS HRAS ERBB4 EGFR

GO Terms for Acneiform Dermatitis

Biological processes related to Acneiform Dermatitis according to GeneCards Suite gene sharing:

(show all 32)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10 NRAS MAP2K1 KRAS HRAS ERBB4 EGFR
2 phosphorylation GO:0016310 9.94 MAP2K1 ERBB4 EGFR BRAF
3 protein phosphorylation GO:0006468 9.92 MAP2K1 ERBB4 EGFR BRAF
4 positive regulation of gene expression GO:0010628 9.88 MAP2K1 KRAS HRAS BRAF
5 heart development GO:0007507 9.83 MAP2K1 ERBB4 CRKL
6 positive regulation of cell proliferation GO:0008284 9.83 KRAS HRAS ERBB4 EGFR CRKL
7 T cell receptor signaling pathway GO:0050852 9.78 HRAS CRKL BRAF
8 animal organ morphogenesis GO:0009887 9.77 HRAS CRKL BRAF
9 negative regulation of neuron apoptotic process GO:0043524 9.74 KRAS HRAS BRAF
10 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.72 NRAS KRAS HRAS
11 liver development GO:0001889 9.7 KRAS HRAS EGFR
12 cellular response to drug GO:0035690 9.67 EGFR CRKL BRAF
13 positive regulation of axonogenesis GO:0050772 9.65 MAP2K1 BRAF
14 positive regulation of Ras protein signal transduction GO:0046579 9.65 HRAS CRKL
15 positive regulation of MAP kinase activity GO:0043406 9.65 KRAS HRAS EGFR
16 regulation of cell motility GO:2000145 9.64 ERBB4 EGFR
17 ERBB2 signaling pathway GO:0038128 9.63 ERBB4 EGFR
18 positive regulation of DNA replication GO:0045740 9.63 HRAS EGFR
19 cellular senescence GO:0090398 9.62 MAP2K1 HRAS
20 peptidyl-tyrosine phosphorylation GO:0018108 9.62 MAP2K1 ERBB4 EGFR BRAF
21 thyroid gland development GO:0030878 9.61 MAP2K1 BRAF
22 regulation of long-term neuronal synaptic plasticity GO:0048169 9.59 KRAS HRAS
23 face development GO:0060324 9.58 MAP2K1 BRAF
24 thymus development GO:0048538 9.58 MAP2K1 CRKL BRAF
25 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.56 MAP2K1 EGFR
26 Ras protein signal transduction GO:0007265 9.56 NRAS KRAS HRAS CRKL
27 positive regulation of protein phosphorylation GO:0001934 9.55 KRAS HRAS ERBB4 EGFR CRKL
28 response to isolation stress GO:0035900 9.54 KRAS HRAS
29 activation of MAPKK activity GO:0000186 9.54 EGFR CRKL BRAF
30 regulation of axon regeneration GO:0048679 9.51 MAP2K1 BRAF
31 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.43 MAP2K1 HRAS ERBB4 EGFR CRKL BRAF
32 MAPK cascade GO:0000165 9.17 NRAS MAP2K1 KRAS HRAS ERBB4 EGFR

Molecular functions related to Acneiform Dermatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 kinase activity GO:0016301 9.71 MAP2K1 ERBB4 EGFR BRAF
2 nucleotide binding GO:0000166 9.7 NRAS MAP2K1 KRAS HRAS ERBB4 EGFR
3 protein kinase activity GO:0004672 9.62 MAP2K1 ERBB4 EGFR BRAF
4 GDP binding GO:0019003 9.43 NRAS KRAS HRAS
5 MAP kinase kinase kinase activity GO:0004709 9.37 EGFR BRAF
6 protein-containing complex binding GO:0044877 9.35 NRAS KRAS HRAS EGFR BRAF
7 protein tyrosine kinase activity GO:0004713 8.92 MAP2K1 ERBB4 EGFR BRAF

Sources for Acneiform Dermatitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....